GALECTIN THERAPEUTICS INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GALECTIN THERAPEUTICS INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $303.00K, a 58.15% decline year-over-year.
- GALECTIN THERAPEUTICS INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $257.00K.
- GALECTIN THERAPEUTICS INC. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $1.13M.
- GALECTIN THERAPEUTICS INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $360.00K.
- GALECTIN THERAPEUTICS INC. stock issued during period, value, stock options exercised for fiscal 2025 was $2.24M, a 180.35% increase from fiscal 2024.
- GALECTIN THERAPEUTICS INC. stock issued during period, value, stock options exercised for fiscal 2024 was $799.00K.
- GALECTIN THERAPEUTICS INC. stock issued during period, value, stock options exercised for fiscal 2020 was $219.00K, a 46.00% increase from fiscal 2019.
- GALECTIN THERAPEUTICS INC. stock issued during period, value, stock options exercised for fiscal 2019 was $150.00K, a 96.02% decline from fiscal 2018.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $303.00K 10-Q · filed 2026-08-14 | $2.05M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $257.00K 10-Q · filed 2026-05-15 | $2.47M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.24M 10-K · filed 2026-03-31 |
| 2025-09-30 | $360.00K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $724.00K 10-Q · filed 2026-08-14 | |
| 2024-12-31 | $799.00K 10-K · filed 2026-03-31 | |
| 2020-12-31 | $219.00K 10-K · filed 2022-03-31 | |
| 2020-06-30 | $44.00K 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $219.00K 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $150.00K 10-K · filed 2021-03-31 | |
| 2018-12-31 | $3.77M 10-K · filed 2020-03-16 | |
| 2014-12-31 | $452.00K 10-K · filed 2016-03-15 | |
| 2013-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $271.00K 10-K · filed 2016-03-15 |
| 2013-09-30 | $94.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | |
| 2013-06-30 | $13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | |
| 2013-03-31 | $77.00K 10-Q · filed 2013-05-10 | |
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-29 | $234.00K 10-K · filed 2013-03-29 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-10 | |
| 2010-12-31 | $128.00K 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |